Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262210810 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Denis Delic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany. Hauptthemen laut MEDLINE: MicroRNAs, Benzhydryl Compounds, Glucosides, Extracellular Vesicles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Vicadrostat, a selective aldosterone synthase inhibitor, reduced albuminuria with concurrent renin–angiotensin system inhibition and empagliflozin, suggesting additive efficacy for chronic kidney disease (CKD) treatment. Specific urinary extracellular vesicle microRNAs (uEV miRNAs) may reflect key mechanisms of kidney injury. We investigated how vicadrostat alone or with empagliflozin affected uEV miRNA expression in study participants. Small RNA sequencing was conducted on uEV miRNAs from 435 participants with CKD who completed 14 weeks treatment in the phase II trial of vicadrostat given with or without empagliflozin. Differentially expressed uEV miRNAs in participants with ≥30% UACR (urine albumin–creatinine ratio) reduction treated with 10 or 20 mg vicadrostat were pooled and evaluated with or without empagliflozin. Changes in miRNA-142-5p correlated significantly with changes in UACR in participants treated with vicadrostat alone, whereas changes in expression of eight additional uEV miRNAs (miR-192-5p, miR-194-5p, miR-6882-5p, miR-27a-5p, miR-381-3p, miR-192-3p, miR-513a-5p, and miR-199b-3p) correlated with ≥30% UACR improvements in patients treated with vicadrostat plus empagliflozin. Cellular deconvolution revealed that these miRNAs were expressed in various kidney cell types. Vicadrostat plus empagliflozin altered uEV miRNAs involved in immunomodulatory and fibrotic pathways irrespective of participant diabetes status. Regulation of miRNAs may provide insights into synergistic mechanisms of vicadrostat and empagliflozin in CKD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany.
- Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, 68167 Heidelberg, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.
- Staburo GmbH, 81549 Munich, Germany.
- Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877, USA.
- Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany.
ORCID-Profile: Denis Delic, Isabella Gashaw, Katherine R Tuttle
Förderung
- Boehringer Ingelheim
Zitieren
APA
Delic, D., Gashaw, I., Duran-Fernandez, I., Cronin, L., Hauske, S. J., Rossing, P., & Tuttle, K. R. (2025). Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210810
Vancouver
Delic D, Gashaw I, Duran-Fernandez I, Cronin L, Hauske SJ, Rossing P, et al. Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210810
BibTeX
@article{Delic2025,
author = {Delic, Denis and Gashaw, Isabella and Duran-Fernandez, Ileana and Cronin, Lisa and Hauske, Sibylle J and Rossing, Peter and Tuttle, Katherine R},
title = {Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262210810}
}
EUVIMED